Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis

Lavalle-Cobo, Augusto, Masson, Walter, Lobo, Martín, Masson, Gerardo, Molinero, Graciela · 2021 · High Blood Pressure & Cardiovascular Prevention

Abstract

Introduction Sodium Glucose Co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) were associated with a reduction in cardiovascular disease events in cardiovascular outcomes trials (CVOTs) in type 2 diabetes. Most of the patients included in these trials received metformin as background therapy. Aim To evaluate the effect of glucagon-like peptide 1 receptor agonists on major cardiovascular events (MACE) and mortality in metformin-naïve patients with type 2 diabetes. Methods A systematic review and meta-analysis of randomized controlled clinical trials of GLP-1RAs on type 2 diabetes population was performed, after searching the PubMed/MEDLINE, Embase, Scielo, Google Scholar and Cochrane Controlled Trials databases. The primary endpoint was MACE. The secondary endpoints were cardiovascular death and all-cause mortality. A meta-analysis of time-to-event outcomes was performed. This meta-analysis was registered in PROSPERO (CRD42021260040) RESULTS: Seven trials, including 11510 patients, were identified and considered eligible for the analyses. GLP-1RAs were associated with a significant reduction in MACE incidence (HR: 0.86, 95% confidence interval: 0.79-0.94; I 2 : 0%). The secondary endpoints analysis showed a non-significant reduction in all-cause mortality (HR: 0.86, 95% confidence interval: 0.73-1.00 I 2 : 0%) and cardiovascular mortality (HR: 0.81, 95% confidence interval: 0.63-1.05; I 2 : 0%). Conclusions In this meta-analysis, GLP-1RAs red…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40292-021-00479-1

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Ferrannini G, Gerstein HC, Colhoun HM, Dagenais R, Diaz R, Dyal L, et al. Cardio protection with dulaglutide is not depending on baseline therapy with metformin: a subgroup analysis of the REWIND trial. Diabetologia. 2020;25:1–485. https://doi.org/10.1007/s00125-020-05221-5. · DOI

Cited by

See all 9

Metadata

Authors
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G.
Affiliations
Hospital Italiano de Buenos Aires (AR)
Venue
High Blood Pressure & Cardiovascular Prevention
Published
2021-10-27
Volume
28
Issue
6
Pages
605-612
ISSN
  • 1120-9879 (ISSN-L)
  • 1179-1985
OpenAlex
W3209687327
Cited by
9
References
44
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 2
FWCI
0.23
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • High Blood Pressure & Cardiovascular Prevention (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, type 2 diabetes, major adverse cardiovascular events, cardiovascular mortality, all-cause mortality, cardioprotection
MeSH terms
Glucagon-Like Peptide-1 Receptor, Cardiotonic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Metformin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. https://app.cochat.ai/papers/10.1007/s40292-021-00479-1
The paper
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021). Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. High Blood Pressure & Cardiovascular Prevention. https://doi.org/10.1007/s40292-021-00479-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.